Covis Pharma cannot rely on real-world evidence alone to confirm the clinical benefit of the preterm birth prevention drug Makena (hydroxyprogesterone caproate), the US FDA’s Center for Drug Evaluation and Research said.
At the forthcoming hearing on CDER’s proposal to withdraw Makena’s accelerated approval, Covis seeks to discuss precedent for agency reliance...








